Treatment of ANCA-Associated Vasculitis
Induction Therapy
- The optimal management for patients with ANCA-associated vasculitis is rituximab plus high-dose glucocorticoids for induction therapy, with cyclophosphamide as an alternative if rituximab is unavailable or contraindicated, according to the Kidney International guidelines and the American College of Rheumatology 1, 2, 3
- High-dose glucocorticoids should be administered with an initial dose of 1 mg/kg/day (not exceeding 80 mg/day) and a pre-specified tapering schedule, as recommended by the Kidney International guidelines and the European Renal Association 1, 2
- Cyclophosphamide can be administered as an IV pulse of 15 mg/kg every 2-3 weeks or orally at 2 mg/kg/day, with age-based dose adjustments and consideration of cumulative dose limitations (>36g associated with increased malignancy risk), according to the Kidney International guidelines and other sources 1, 4, 5
Maintenance Therapy
- Rituximab maintenance therapy should be continued for at least 18-24 months after achieving remission, with options including 500 mg every 6 months or 1000 mg at remission and at months 4, 8, 12, and 16, as recommended by the Kidney International guidelines and the American College of Rheumatology 1, 2
- Azathioprine can be used as an alternative maintenance therapy at a dose of 1.5-2 mg/kg/day for 18-24 months, then decreased to 1 mg/kg/day until 4 years after diagnosis, according to the Kidney International guidelines 1
- Methotrexate can be considered if GFR >60 ml/min/1.73 m², and mycophenolate mofetil can be used if other options are not tolerated, although it is less effective than azathioprine, as suggested by various guidelines and sources 5, 1, 6
Monitoring and Prophylaxis
- Regular ophthalmologic examinations are essential to assess retinal vasculitis response, and patients should be monitored for hypogammaglobulinemia, which occurs in up to 58% of patients treated with rituximab, according to the Kidney International guidelines and other sources 1, 7
- Pneumocystis jirovecii pneumonia prophylaxis is mandatory for patients receiving rituximab or cyclophosphamide, as recommended by the Kidney International guidelines and the Infectious Diseases Society of America 1, 2
- Complete blood count with differential, comprehensive metabolic panel, urinalysis and urine protein-to-creatinine ratio, and inflammatory markers (ESR and CRP) are used to assess disease activity and organ involvement, as suggested by various sources 7, 1
Relapse Management
- Severe relapse should be treated with re-induction using rituximab, which is preferred over cyclophosphamide, according to the Arthritis and Rheumatology guidelines and the American College of Rheumatology 2, 3
- Non-severe relapse should be managed by adjusting current immunosuppressive therapy based on clinical features, although the specific guidelines for this are not provided in the article
- Life-threatening manifestations may benefit from plasma exchange in addition to standard immunosuppression, as suggested by various sources 8, 6, 1
Special Considerations
- PR3-ANCA positive patients have higher remission rates with rituximab compared to cyclophosphamide, and should be considered for extended therapy (up to 4 years) due to higher relapse risk, according to the Kidney International guidelines and other sources 1, 3, 2
- Premature discontinuation of maintenance therapy, especially in PR3-ANCA positive patients, should be avoided due to higher relapse risk, as recommended by the Kidney International guidelines and the European Renal Association 1, 2
- The presence of extrarenal manifestations should raise suspicion for systemic vasculitis as the underlying cause of RPGN, and pulmonary-renal syndrome specifically suggests AAV or anti-GBM disease, as suggested by various sources 8, 1
Diagnostic Workup
- The diagnostic workup for Granulomatosis with Polyangiitis (GPA) requires comprehensive laboratory testing, imaging studies, and often tissue biopsy to confirm the diagnosis and assess organ involvement, with ANCA testing being essential for all suspected cases, as suggested by various sources 7, 1
- Chest radiograph and/or high-resolution CT, sinus CT scan, and abdominal ultrasonography are used to identify pulmonary nodules, infiltrates, cavities, and assess organ involvement, as recommended by various guidelines and sources 7, 1
- ENT consultation with nasal endoscopy, ophthalmologic examination, pulmonary function tests, and audiometry are used to evaluate upper airway involvement, ocular manifestations, lung function, and hearing loss, as suggested by various sources 7, 1
Prognosis and Outcome
- With modern treatment regimens, the prognosis of GPA has significantly improved, with a 10-year survival rate estimated at 40% with kidney involvement and 60-70% without kidney involvement, and regular monitoring for disease activity, treatment response, medication side effects, and infection is essential to prevent organ damage and improve outcomes in patients with GPA, as suggested by various sources 3, 9, 1